Corient Private Wealth
PMVP icon

Corient Private Wealth’s PMV Pharmaceuticals PMVP Stock Holding History

Corient Private Wealth’s Portfolio PMVP Stock Details PMVP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.1K Hold
15,000
– – ﹤0.01% 3024
2026
Q1 		$18.6K Buy
+15,000
New +$19.1K ﹤0.01% 2786
2025
Q3 		– Sell
-10,000
Closed -$10.6K – 2648
2025
Q2 		$10.6K Hold
10,000
– – ﹤0.01% 2421
2025
Q1 		$10.9K Hold
10,000
– – ﹤0.01% 2263
2024
Q4 		$15.1K Hold
10,000
– – ﹤0.01% 2313
2024
Q3 		$14.9K Hold
10,000
– – ﹤0.01% 2439
2024
Q2 		$16.2K Hold
10,000
– – ﹤0.01% 2299
2024
Q1 		$17K Hold
10,000
– – ﹤0.01% 2266
2023
Q4 		$31K Buy
+10,000
New +$26.5K ﹤0.01% 2218

Other funds holding PMVP

BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Sio Capital Management
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
EC
Euclidean Capital New York $440M AUM 28.33% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ArrowMark Colorado Holdings
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Eversept Partners
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Corient Private Wealth's PMVP Position: Q2 2026 in Review

Corient Private Wealth held its PMV Pharmaceuticals (PMVP) position steady in Q2 2026 at 15,000 shares worth $20.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3024.

Corient Private Wealth first reported a position in PMVP in Q4 2023 and has held it in 9 quarters since. The position peaked at $31K in Q4 2023. 64 funds tracked by Wall St. Rank hold PMVP as of Q2 2026.

  • Corient Private Wealth held 15,000 shares of PMV Pharmaceuticals worth $20.1K as of Q2 2026.
  • Corient Private Wealth left its PMV Pharmaceuticals share count unchanged in Q2 2026.
  • PMV Pharmaceuticals made up ﹤0.01% of Corient Private Wealth's portfolio in Q2 2026, its #3024 holding.
  • Corient Private Wealth first reported a position in PMV Pharmaceuticals in Q4 2023 and has held it in 9 quarters since.
  • Corient Private Wealth's PMV Pharmaceuticals position peaked at $31K in Q4 2023.
  • 64 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q2 2026.

Based on Corient Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.